Table 1. . Presenting patient and clinicopathologic tumor characteristics among 385 node-positive cutaneous melanoma patients treated with (nn = 128) and without (nn = 257) adjuvant interferon.
| Characteristics | Classification | All patients (n = 385), n (%) | Interferon (n = 128), n (%) | No adjuvant therapy (n = 257), n (%) | p-value |
|---|---|---|---|---|---|
| Median age (years, range) | 59 (14–91) | 50 (14–80) | 65 (14–91) | <0.001 | |
| Sex | Female | 128 (33.2) | 44 (34.4) | 84 (32.7) | 0.74 |
| Male | 257 (66.8) | 84 (65.6) | 173 (67.3) | – | |
| Tumor T stage | T1 | 11 (2.9) | 4 (3.1) | 7 (2.7) | 0.58 |
| T2 | 62 (16.1) | 24 (18.8) | 38 (14.8) | – | |
| T3 | 147 (38.2) | 42 (32.8) | 105 (40.9) | – | |
| T4 | 130 (33.8) | 47 (36.7) | 83 (32.3) | – | |
| T0 | 35 (9.1) | 11 (8.6) | 24 (9.3) | – | |
| LND site | Groin | 87 (22.6) | 30 (23.4) | 57 (22.2) | 0.86 |
| Head and neck | 77 (20) | 27 (21.1) | 50 (19.5) | – | |
| Axilla | 221 (57.4) | 71 (55.5) | 150 (58.4) | – | |
| Median LNs positive, n (range) | 2 (1–34) | 2 (1–34) | 2 (1–22) | 0.53 | |
| Tumor N stage | N1a/N2a | 217 (56.4) | 76 (59.4) | 141 (54.9) | 0.4 |
| N1b/N2b/N3 | 168 (43.6) | 52 (40.6) | 116 (45.1) | – | |
| N1 | 170 (44.2) | 60 (46.9) | 110 (42.8) | 0.68 | |
| N2 | 87 (22.6) | 29 (22.7) | 58 (22.6) | – | |
| N3 | 128 (33.2) | 39 (30.5) | 89 (34.6) | – | |
| Extranodal extension | Absent | 254 (66.0) | 84 (65.6) | 170 (66.1) | 0.92 |
| Present | 131 (34.0) | 44 (34.4) | 87 (33.9) | – | |
| Median LN size, cm (range) | 2.0 (0.3–15) | 2.0 (0.5–8.0) | 2.2 (0.3–15.0) | 0.11 | |
| Regional radiation therapy? | No | 305 (79.2) | 99 (77.3) | 206 (80.2) | 0.52 |
| Yes | 80 (20.8) | 29 (22.7) | 51 (19.8) | – | |
LN: Lymph node; LND: Lymph node dissection.